Despite the legalization of psilocybin therapy for depression in terminal illnesses such as advanced cancer through Oregon’s Measure 109 in 2020, significant challenges have impeded its implementation. This review synthesizes the empirical data supporting the utilization of psilocybin therapy for addressing cancer-related depression, including an evaluation of its purported benefits and potential adverse effects. It provides a comprehensive examination of therapeutic strategies, dosing regimens, and barriers to ensuring responsible and equitable access. Salient issues explored include the development of ethical protocols, integration within healthcare systems, ensuring statewide availability, resolving legal ambiguities, and defining clinical standards. Oregon’s pioneering role serves as a case study, highlighting the necessity of addressing regulatory, logistical, and ethical obstacles to ensure the establishment of rigorous and equitable psilocybin care models.
尽管俄勒冈州2020年通过的109号法案已将裸盖菇素疗法针对晚期癌症等终末期疾病抑郁症状的治疗合法化，但其实际推行仍面临重大挑战。本综述整合了支持使用裸盖菇素疗法治疗癌症相关抑郁症的实证数据，包括对其宣称疗效与潜在副作用的评估。文章系统考察了治疗策略、给药方案以及确保负责任且公平获取该疗法的主要障碍，重点探讨了伦理规程制定、医疗体系整合、全州可及性保障、法律模糊性澄清及临床标准界定等核心议题。以俄勒冈州的实践为案例，研究强调必须解决监管、运营及伦理层面的障碍，以建立严谨且公平的裸盖菇素治疗模式。
Review of Psilocybin Use for Depression among Cancer Patients after Approval in Oregon
肿瘤(癌症)患者之家